Neuronetics, Inc.
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Daniel L. Reuvers
- Full Time Employees
- 658
- Sector
- Health technology
- Industry
- Medical specialties
- Address
- 3222 Phoenixville Pike Malvern PA United States 19355
- IPO Date
- Jun 28, 2018
- CIK
- 0001227636
- Website
- neurostar.com
- Similar Companies
- Business
- Neuronetics, Inc. (NASDAQ: STIM) develops and commercializes non-invasive transcranial magnetic stimulation (TMS) therapies for psychiatric and neurological disorders, primarily targeting patients with major depressive disorder (MDD), obsessive-compulsive disorder (OCD), and anxious depression; its core offering is the NeuroStar Advanced Therapy System, an FDA-cleared office-based device that delivers MRI-strength magnetic pulses to stimulate brain regions associated with mood regulation, supplemented by the TrakStar cloud-based platform for patient data management, treatment tracking, and outcome analytics; additional services encompass clinical training, reimbursement support, and provider practice optimization tools. Founded in 2003 and headquartered in Malvern, Pennsylvania, the company operates primarily in the United States through a network of provider practices and internationally in select markets, serving psychiatrists, mental health professionals, and treatment-resistant patients across adolescent (ages 15-21), adult, and Medicare populations. In December 2024, Neuronetics completed the acquisition of Greenbrook TMS Inc., integrating over 95 U.S. treatment clinics to expand its service delivery model and realize over $22 million in annualized cost synergies while targeting double-digit revenue growth and cash flow positivity in 2025; recent FDA clearances extend NeuroStar use as an adjunct to antidepressants in adolescents with MDD, alongside expanded insurer coverage including TRICARE in 23 states, Cigna, Aetna, Humana, and Medicare; the company also launched the Better Me Provider network to boost patient treatment volumes and announced strategic partnerships such as a five-year exclusive alliance with Transformations Care Network.
Company News
Neuronetics to Report Third Quarter 2026 Financial and Operating Results and Host Conference Call
Neuronetics, Inc. (NASDAQ:STIM) Stock Now Rated “Moderate Buy” by Sell-Side Brokerages
NeuroStar Advances Practice Innovation with First-Ever TMS Integration with an EHR/EMR System
Neuronetics, Inc. (STIM) Q2 2026 Earnings Call Transcript
Neuronetics Q2 Earnings Call Highlights
Neuronetics (STIM) Reports Q2 Loss, Beats Revenue Estimates
Neuronetics and Jorey Chernett Announce Shared Vision
Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Greenbrook Opens National Center of Excellence for Advanced Interventional Psychiatry in Rockville, Maryland
Neuronetics to Report Second Quarter 2026 Financial and Operating Results and Host Conference Call
Neuronetics Appoints Nir Naor Chief Financial Officer; Announces Additional Management Changes
Why Is Neuronetics Stock Soaring Monday?
Neuronetics: Top Line Growth, Low Valuation, But Gross Margin Struggles
Neuronetics to Participate in a Panel Discussion at B. Riley Securities' Mind, Muscle & Vision Summit on July 16, 2026
Neuronetics Appoints Robert Greene as Senior Vice President Sales
Neuronetics Highlights Continued Advancements in TMS Research at CTMSS 2026
Neuronetics and ANT Neuro Announce Strategic Collaboration to Integrate Neuronavigation with NeuroStar TMS Treatment
Neuronetics, Inc. (STIM) Q1 2026 Earnings Call Transcript
Neuronetics (STIM) Reports Q1 Loss, Tops Revenue Estimates
Neuronetics Reports First Quarter 2026 Financial and Operating Results